CD274 and non-small cell lung carcinoma: In this cohort study, a history of PPI use was independently associated with worse treatment outcomes in patients with NSCLC with a PD-L1 TPS of 50% or more who were treated with pembrolizumab monotherapy but not those treated with ICI plus chemotherapy.